title: A pilot study evaluating anxiety and depressive scores in acne patients treated with isotretinoin.
abstract: BACKGROUND
  Isotretinoin therapy and its alleged adverse psychiatric effects have received considerable media attention during the past years. The aim of this pilot study was to investigate whether there was any association between isotretinoin therapy and anxiety, depression or suicidal ideation.
  
  
  METHODS
  Forty-five patients with severe recalcitrant acne were enrolled in this study. Isotretinoin was administered at a dose of 0.5-1 mg/kg per day in two divided doses with food for 16 weeks. All patients received a complete dermatological examination and the severity levels of their acne were scored according to the Leeds Revised Acne Grading system at baseline (before isotretinoin treatment) and follow-up assessments at weeks 4, 8 and 16 of the treatment. Severity of anxiety and depressive symptoms were assessed with the Clinical Anxiety Scale and Montgomery-Asberg Depression Rating Scale before and upon completion of the 16-week isotretinoin treatment.
  
  
  RESULTS
  Twenty-three patients completed the final assessment. There was a statistically significant decrease in anxiety scores. Depression scores also decreased but were not statistically significant. No patient committed or attempted suicide.
  
  
  CONCLUSIONS
  This pilot study was unable to detect an association between the use of isotretinoin and an increased risk for anxiety, depression, or suicidal thoughts.
authors.affiliation: Department of Dermatology, University of Ericyes, School of Medicine, Kayseri, Turkey. ferhbas@ericyes.edu.tr
authors.forename: Ayten
authors.initials: A
authors.lastname: Ferahbas
authors.forename: M Tayfun
authors.initials: MT
authors.lastname: Turan
authors.forename: Ertugrul
authors.initials: E
authors.lastname: Esel
authors.forename: Serap
authors.initials: S
authors.lastname: Utas
authors.forename: Caner
authors.initials: C
authors.lastname: Kutlugun
authors.forename: Canan Gul
authors.initials: CG
authors.lastname: Kilic
mesh_terms: D000152:Acne Vulgaris / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001007:Anxiety / Q000139:chemically induced; D001219:Aspartate Aminotransferases / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003866:Depressive Disorder / Q000175:diagnosis*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008347:Manifest Anxiety Scale; D010865:Pilot Projects; D012720:Severity of Illness Index; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D003879:Dermatologic Agents; D014280:Triglycerides; D002784:Cholesterol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D015474:Isotretinoin